Premium
Postvaccinal Encephalitis after ChAdOx1 nCov ‐19
Author(s) -
Zuhorn Frédéric,
Graf Tilmann,
Klingebiel Randolf,
Schäbitz WolfRüdiger,
Rogalewski Andreas
Publication year - 2021
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.26182
Subject(s) - medicine , pandemic , vaccination , encephalitis , incidence (geometry) , covid-19 , observational study , autoimmune encephalitis , immunology , virology , pediatrics , intensive care medicine , disease , virus , infectious disease (medical specialty) , physics , optics
The global SARS‐CoV‐2 pandemic has contributed to more than 163 million confirmed infections and 3.3 million deaths worldwide. The severity of the pandemic has led to an unprecedented effort to develop multiple effective vaccines. Due to excellent safety and efficacy data from clinical trials, several vaccines were approved. We report a case series of postvaccinal encephalitis in temporal correlation to vaccination with ChAdOx1 nCov‐19. The diagnostic criteria for possible autoimmune encephalitis were fulfilled. Our patients responded well to immunosuppressive therapy with corticosteroids. The incidence has been estimated to be approximately 8 per 10 million vaccine doses. Complication of postvaccinal encephalitis after ChAdOx1 nCoV‐19 vaccination still appear to be very rare, but need to be diagnosed and treated adequately. Large pooled data from observational epidemiologic studies are necessary to verify causality. ANN NEUROL 2021;90:506–511